Welcome to our dedicated page for IPG PHOTONICS SEC filings (Ticker: IPGP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IPG PHOTONICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IPG PHOTONICS's regulatory disclosures and financial reporting.
IPG Photonics Corporation (IPGP) has entered into a definitive Share Purchase Agreement to acquire 100% of Lumibird Medical, a French subsidiary of Lumibird S.A. The agreement follows the seller’s exercise of a previously disclosed put option.
The purchase price is €300 million on a cash-free, debt-free basis, payable in cash at closing and subject to customary adjustments, plus up to €50 million in contingent earn-out consideration tied to 2026 and 2027 performance metrics. IPG Photonics expects to fund the deal with cash on hand. The parties have put in place a warranty and indemnity insurance policy, with the seller providing fundamental representations and limited business warranties. Closing is subject to customary conditions, including French foreign direct investment approval and an AMF waiver, and is expected in the fourth quarter of 2026.
IPG PHOTONICS CORP (IPGP) reported that Valentin Gapontsev Trust I, a ten percent owner, sold an aggregate of 27,397 shares of Common Stock in open-market transactions on September 1–2, 2026. The sales, executed at weighted average prices around the mid‑$70s per share, were made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
IPG PHOTONICS CORP (IPGP) director John R. Peeler reported two open-market purchases of common stock on August 26, 2026. He bought 1,552 shares at a weighted average price of $72.84 per share (with individual trades between $72.44 and $73.37), and 1,158 shares at a weighted average price of $74.57 per share (with trades between $74.12 and $75.07). In total, Peeler purchased 2,710 shares in direct ownership.
IPG Photonics Corp executive Paulus Bucher, SVP Global Operations, reported a disposition of 663 shares of common stock on 2026-08-08. The shares were withheld to cover taxes on vested restricted stock units, at a value of $90.23 per share, leaving him with 6,053 directly held shares.
IP Fibre Devices Ltd, a more-than-10% owner of IPG Photonics Corp, reported selling a total of 30,313 shares of common stock in multiple open market or private transactions on August 4–5, 2026. The sales were executed at weighted average prices between $95.18 and $98.71 per share, with individual trades occurring within the price ranges disclosed for each tranche. All transactions were carried out under a Rule 10b5-1 trading plan adopted on March 17, 2026.
First Eagle Investment Management, LLC filed an amended Schedule 13G reporting beneficial ownership of 3,339,101.48 shares of IPG Photonics Corp common stock, representing 7.87% of the shares believed outstanding. First Eagle has sole voting power over 3,012,312 shares and sole dispositive power over 3,339,101.48 shares, with no shared voting or dispositive power.
The First Eagle Global Fund, a registered investment company advised by First Eagle, may be deemed to beneficially own 2,350,213 of these shares, or 5.54% of IPG Photonics’ common stock. The shares are held principally on behalf of investment advisory clients, who have the right to receive dividends and sale proceeds.
IPG Photonics Corp shareholder IP Fibre Devices Ltd, a ten percent owner, reported selling 27,000 shares of common stock on July 31, 2026. The sales were executed in multiple open-market transactions at weighted average prices of $85.76 and $86.14, with additional blocks at $87.45 and $88.59, under a Rule 10b5-1 trading plan adopted March 17, 2026.
Eugene A. Scherbakov, a director and 10% owner of IPG Photonics Corp, reported selling 1,524 shares of common stock on July 31, 2026. The four non-derivative sales were executed at weighted average prices from $85.72 to $88.68 per share, in price ranges detailed for each trade. All transactions were effected under a Rule 10b5-1 trading plan adopted on March 17, 2026.
IPG Photonics reported Q2 2026 net sales of about $278.6M, up 11.1% year over year, with first‑half sales near $544.1M, up 13.7%. Growth was driven by Industrial Solutions, especially welding, cleaning, marking and services, while Advanced Solutions declined. Gross margin improved to 40.4% from 37.3%, helped by lower product costs and $4.7M of tariff refunds that added about 170 basis points, partly offset by higher unabsorbed manufacturing costs.
Despite stronger revenue, net income fell to $5.2M in Q2 and $6.8M for the first half, constrained by a high tax rate and non‑recurring items. The company booked a $17.6M impairment tied to the planned sale of its Belarus operations, now classified as held for sale, and a $13.3M patent litigation settlement with Trumpf. Operating cash flow strengthened to $32.3M in the first half, with $399.2M of cash and $472.1M of short‑term investments and no borrowings under a revolving credit facility. After quarter‑end IPG signed a put option to acquire Lumibird Medical for €300,000 plus up to €50,000 earn‑out, expected to close in the fourth quarter of 2026 subject to French approvals.
IPG Photonics reported second quarter 2026 revenue of $278.6 million, up 11% year over year, with GAAP gross margin improving to 40.4%. Operating income was $4.5 million, and GAAP net income declined 21% to $5.2 million, or $0.12 per diluted share, partly reflecting impairment charges of $17,574 (in thousands) and a 58% tax rate.
Industrial Solutions revenue grew 16% year over year and represented 85% of total sales, while Advanced Solutions revenue decreased. Emerging growth products contributed 58% of revenue. Adjusted gross margin was 40.7%, adjusted EBITDA rose 54% to $48.5 million, and adjusted EPS increased 93% to $0.58. The company generated $37.8 million of operating cash flow and invested $20.7 million in capital expenditures. For the third quarter of 2026, guidance calls for revenue of $265–$295 million, adjusted gross margin of 37.5%–40.5%, adjusted operating expenses of $92–$95 million, adjusted EPS of $0.30–$0.60, and adjusted EBITDA of $35–$51 million.